Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

A 50% confirmed ORR in early evaluable UPS/DDLPS cases contrasts with historical second-line benchmarks of <5% ORR, mPFS ~2–3 months, and mOS ~9–10 months ...

Iovance Biotherapeutics shares rose after the company shared positive trial results from a treatment designed for soft tissue cancer. The stock gained 26% to $3.65 Tuesday. Shares are still down 32% ...

SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions. STS is a rare cancer that originates as an abnormal growth ...

Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft ...

Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft ...

Novel biomarkers like GDF15 and OPN show promise in diagnosing and prognosticating uterine sarcoma, potentially enabling early identification and tailored therapy. Blood-based markers such as NLR and ...

Efficacy and Tolerability of a Low-Dose Continuous Regimen of Regorafenib in Refractory Synovial Sarcomas: A Single-Arm, Phase II Trial From India Diagnostic concordance was observed in 296 cases ...

Resolute Science Inc.’s RS-5 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcomas.